Download Full Text (1.8 MB)


Because of its β− and γ decay routes, 67Cu is a very promising radioisotope for use in theranostic cancer treatments. Currently, 67Cu is produced through the irradiation of either 68Zn or 67Zn in a cyclotron, a traditional nuclear reactor or a linear electron accelerator. Once formed, a small amount of copper (nanograms) has to be separated from the large amount of remaining zinc (grams) and undesired byproduct isotopes such as 66Ga, 67Ga, 64Cu, 61Cu, 58Co. Currently, such separations are performed in resin-packed columns and can require 4 h to purify a 5 g target. These procedures may involve multiple columns and require the target to be dissolved and reconstituted several times in different solutions and concentrations of acids. The complexity and length of resin-based separations combined with the 2.58-day half-life of 67Cu has caused a shortage of 67Cu for research and clinical trials.

Symposium Date

Fall 12-1-2012


membrane adsorber, Cu-67, AGET ATRP


Chemical Engineering

Creative Commons License

Creative Commons Attribution-NonCommercial 4.0 International License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Membrane Separation of Cu-67 for Use in Theranostics